SCHEMBL4841261

SCHEMBL4841261

CC(C)(C)OC(=O)CC(CC(=O)NOC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)NCCc1ccc(-c2ccc(C#N)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.46
HPGD P15428 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
CA2 P00918 2/20 0.40
CTSS P25774 2/20 0.40
CTSK P43235 2/20 0.40
MMP2 P08253 2/20 0.40
MMP3 P08254 2/20 0.40
CA9 Q16790 1/20 0.38
ESRRG P62508 1/20 0.38
EP300 Q09472 4/20 0.38
PPARA Q07869 1/20 0.37
MMP12 P39900 1/20 0.37
MMP13 P45452 1/20 0.37
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37
MMP1 P03956 1/20 0.36
PRSS1 P07477 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4839942 0.93 CA2 (0.45) CA2CTSSCTSKMMP2MMP3
SCHEMBL4840798 0.91 MMP2 (0.45) CA2MMP2MMP3CA9ESRRG
SCHEMBL4840314 0.88 CA2 (0.40) CA2CTSSCTSKMMP2MMP3
SCHEMBL4835699 0.86 SMN1; SMN2 (0.43) HPGDPOLBMAPTCA2CA9
SCHEMBL4831392 0.85 CA2 (0.43) CA2CTSSCTSKMMP2MMP3
SCHEMBL4838858 0.85 CA2 (0.39) ABCB1ABCG2CA2MMP3CA9
SCHEMBL4831283 0.84 CA2 (0.49) CA2CTSSCTSKCA9MMP9
SCHEMBL4886128 0.83 KMT2A (0.45) HPGDPOLBMAPTCA2MMP2
SCHEMBL6253965 0.82 MMEL1 (0.51) CA2MMP2MMP3CA9ESRRG
SCHEMBL4838164 0.80 NPC1 (0.48) HPGDPOLBCA2MMP3CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2006-12-21 US disclosed
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US disclosed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US disclosed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX GLS, SUCNR1, PGD ABCB1 3147/4885HPGD 96/4885ABCG2 2140/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD ABCB1 3060/4885HPGD 94/4885ABCG2 2103/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH ABCB1 3106/4885HPGD 86/4885ABCG2 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.